Skip to main content
< Back to news
 29.04.2025

Gate2Brain Confirms Breakthrough Antibody Delivery Technology to the Brain, Paving the Way for Next-Generation CNS Therapies

New studies emphasize how peptide-based launchers, the core of Gate2Brain‘s technological platform, are poised to revolutionize drug delivery across the blood-brain barrier. Two groundbreaking articles, published in Molecular Pharmaceutics, have strongly validated the versatility of the company’s platform as a system capable of transporting a wide range of therapeutic agents across the blood-brain barrier (BBB).

Gate2Brain’s technology, a spinoff from the University of Barcelona (UB), the Institute for Bioengineering of Catalonia (IRB Barcelona), and the Sant Joan de Déu Research Institute (IRSJD) – Hospital Sant Joan de Déu (SJD), is especially significant for antibody-based therapies, which, despite their potential, are often limited by their poor accessibility to the brain. These findings demonstrate that, both in the administration of monoclonal antibodies and other therapeutic modalities, Gate2Brain’s innovative brain-targeting peptides can overcome one of the greatest challenges in modern medicine.

Both studies, featuring the involvement of Meritxell Teixidó, CEO and CSO of Gate2Brain, highlight the transformative impact of the company’s peptide launchers in the administration of brain-targeted drugs. The findings open new avenues for treating central nervous system diseases, including brain metastases, glioblastoma, Alzheimer’s, and other neurodegenerative disorders, further reinforcing Gate2Brain’s approach to achieving better treatments by improving drug delivery to the site of action. We are witnessing the next generation of tools to cross the blood-brain barrier and effectively deliver a wide range of drugs and advanced therapies to the brain.

Advancing Drug Delivery Across the BBB with Gate2Brain Technology

The first study provides compelling evidence that precise chemical modifications enable the targeted delivery of large biomolecules to the brain. The MiniAp-4–trastuzumab conjugate not only maintains therapeutic efficacy but also achieves significantly improved brain penetration, demonstrating a protective effect against brain metastasis in preclinical models. These results validate the Gate2Brain technology platform, suggesting that MiniAp-4 could potentially protect the brain from metastases by improving the delivery of drugs to protect it.

The second study offers a comprehensive review of the evolution and innovation in brain shuttle peptides over the past decade. It emphasizes the advantages of receptor-mediated transcytosis (RMT) and the latest strategies in peptide engineering to enhance drug delivery across the BBB. This work further substantiates the Gate2Brain platform’s ability to efficiently transport a broad spectrum of therapeutic agents.

Together, these studies reinforce the concept that advanced peptide-based brain
shuttle technologies—central to the Gate2Brain platform—are dynamic and adaptable tools for overcoming the challenges of brain drug delivery. This breakthrough holds great promise for accelerating the clinical translation of new treatments for a wide range of neurological disorders, where there is a candidate drug that needs a better transport. Giving an opportunity to all those suffering from brain diseases.

» Articles of reference:

Mariam Masmudi-Martín, Benjamí Oller-Salvia, María Perea, Meritxell Teixidó, Manuel Valiente, Ernest Giralt, and Macarena Sánchez-Navarro. Molecular Pharmaceutics 2025 22 (3), 1384-1395. doi: 10.1021/acs.molpharmaceut.4c01091

Roger Prades, Meritxell Teixidó, and Benjamí Oller-Salvia. Molecular Pharmaceutics 2025 22 (3), 1100-1109. doi: 10.1021/acs.molpharmaceut.4c01327

» Link to the news: web de Gate2Brain [+]